Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Combination With R-PolaCHP for Newly Diagnosed DLBCL
NCT04850495Phase 1Active, not recruiting
- Start
- Nov 2021
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Incidence of adverse events at 24 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04850495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850495.